Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity

Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity

US Patent 8236304 · Granted Aug 7, 2012

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Treatment of diseases by concurrently eliciting remyelination effects and immuno2025
VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergi2024
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders2024
Vista antagonist and methods of use2024
Anti-CD25 antibody agents2024
Method of treating cancer or depleting regulatory T cells in a subject by admini2024
Anti-CD25 for tumour specific cell depletion2024
Anti-CD25 for tumour specific cell depletion2023
Anti-CD25 for tumour specific cell depletion2023
Anti-CD25 antibody agents2023
Anti-CD25 for tumour specific cell depletion2023
Autoimmune disorder treatment using RXR agonists2023